Arrowhead's ARO-HIF2 Shows Early Signs Of Efficacy In Type Of Kidney Cancer

Arrowhead Pharmaceuticals Inc ARWR has announced interim results from the first two cohorts of Phase 1b study of ARO-HIF2 for clear cell renal cell carcinoma (ccRCC).
ARO-HIF2 is the first tumor-targeted investigational medicine to utilizing Arrowhead's Targeted RNAi Molecule (TRiM) platform.
Arrowhead is currently enrolling in the third planned patient cohort.
In seventeen patients treated with investigational ARO-HIF2, nine had tumor biopsy material that could be evaluated.
Seven of these nine tumor samples demonstrated reductions in HIF2α protein, as measured by immunohistochemistry H-score.
The mean of these reductions was -48%, with a range from -9% to -82%.
In addition, one patient achieved a partial response with tumor shrinkage of approximately 65%, and four additional patients in cohort 2 remain on study drug with stable disease.
To date, investigational ARO-HIF2 has been generally well tolerated at doses of up to 525 mg weekly, and no cases of anemia related to the drug have been reported.
Price Action: ARWR shares are up 1.05% at $63.79 during the market session on the last check Tuesday.